EZH2 and neoplasm: Besides the ‘classical' oncogenic properties of EZH2 (refs 14, 15, 16), recent evidence has pointed also to a tumour suppressor role manifested through either inactivating mutations of PRC2 members17, 18 or histone mutations that were shown to inhibit PRC2 activity19, 20.